Rezera reports positive Phase 2 results, plans PAD trial in H1 2027
AI Summary- Rezera reported positive topline results from its Phase 2 RESOLVE-1 trial of ruvonoflast.
- Ruvonoflast reduced hsCRP at 150 mg/day and 300 mg/day through week 24.
- Rezera plans to begin a Phase 3 PAD study in the first half of 2027.